Close Menu

University of California

Off Their Boards

More than two dozen University of California researchers are taking a break from their positions on the editorial boards of Elsevier journals, according to ScienceInsider.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

The University of California has decided to not renew its subscription with the scientific publisher Elsevier.

Stat News reports that the University of California and publisher Elsevier are fighting over open-access journal payments.

In PNAS this week: germline variants influence tumor immune gene expression in two dozen cancer types, phylogenetic relationships of hemipteroid insects, and more.

Three studies encompassing dozens of ancient genomes are offering a closer look at complex historical population spread in North, Central, and South America.

A federal appeals court in the US has upheld a judgment that gave the Broad Institute key CRISPR patents.

Researchers used CRISPR to engineer mice that have multiple genetic variants associated with late-onset AD to facilitate research into biomarkers and treatments.

The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.

A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.

Pages

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.